|
|
|
| home > ebr > winter 2022 > modelling genetic disease: ips cell line development using gene editing |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review
|
The development of therapeutic treatments is a complex process linked to the ability to understand mechanisms underlying human disorders by studying them in human cell models. Patient-to-patient genetic diversity creates additional layers of technical complexity when making the leap to personalised medicine. Major advancements in pluripotent stem cell and CRISPR-Cas9 gene editing technologies have unlocked enormous potential in the generation of isogenic model cell lines, engineered to study a wide range of diseases in an increasing number of cell and tissue types derived from the pluripotent state. However, challenges remain as successful isolation of clonal human induced pluripotent stem (iPS) cell lines that are edited in a genetically precise, intended manner is notoriously difficult due to the hurdles of precision and efficiency. Fortunately, there is a growing body of available resources, methods, and services to support researchers in the development of human models of disease for basic research and screening studies.
Generating a Model of Genetic Disease
CRISPR-Cas9 has entered the vernacular with speed and influence, rivalled only by the impact this technology has had on the advancement of understanding cellular health and disease. Human diseases that arise from genetic abnormalities vary greatly in nature and scope. In one disease a single base change can be the difference between sickness and health, whereas in others, large insertions or deletions (INDELs) affect the phenotype. There are some diseases where it is thought that a combination of single nucleotide changes and/or INDELs spread across a gene – or genes – results in disease.
As the CRISPR-Cas9 toolbox has expanded, the ability to model more complicated genetic diseases has grown and the generation of cell models with multiple gene knockouts or larger INDELs is now possible. In fact, the generation of clonal iPS cell lines with specific point mutations, knockouts, conditional knock-outs or knock-ins, tagged proteins, translocations, and even genomic landing pads can be commercially provided (1). Base editing technologies have also developed over the last several years, but their editing window is limited to the four transition mutations (C→T, A→G, G→A and T→C). Though currently unable to make any combination of base-to-base change, this is an area of active study and innovation with rapid advances in technological development widening the scope of its potential (2).
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Life Science and Healthcare Industry Executive Adam Deutsch Joins uMotif Board as Company Brings the Next-Generation of eCOA/ePRO to Expanding Global Market
BOSTON, Mass. – March 15, 2023 —uMotif –
one of the clinical trial technology market’s fastest growing companies
– bolstered its status as the leader in next-generation eCOA/ePRO with
the announcement that life science and healthcare executive Adam Deutsch
has joined its Board of Directors.
More info >> |
|
 |
White Papers |
 |
|
Interface: Drug Delivery Devices
Phillips-Medisize
A family is packing for its annual summer trek to the cottage by the lake. Along with fishing gear, sunscreen, and life vests, the checklist also includes another kind of life saver – an autoinjector that delivers two doses of epinephrine to treat anaphylaxis, a severe and potentially lifethreatening allergic reaction.
More info >> |
|
|
